Cadila Healthcare share price: Sharekhan Retains Buy rating with a revised price target of Rs 560
Cadila Healthcare reported a healthy set of results for Q3 FY21, though earnings missed estimates marginally, following a marginal miss in revenue. Consolidated sales at Rs 3796 cr grew by 4% yoy, driven by strong growth in India business, up 19.5% yoy. While the US business was weak, declining by around 4% yoy due to a weak flu season coupled with some inventory correction.
Cadila Healthcare highlights operating profit margin (OPM) for the Q3 expanded by 220 bps yoy to 21.3%, led by savings in other expenses: Reuters